Aerie Pharmaceuticals Inc., of Durham, N.C., appointed Charlene E. Davis vice president and chief compliance officer.
Aeterna Zentaris Inc., of Charleston, S.C., appointed Klaus Paulini president and CEO and to its board.
Ascletis Pharma Inc., of Hangzhou, China, appointed Handan He chief scientific officer.
Autolus Therapeutics plc, of London, appointed David Brochu senior vice president, head of product delivery, and Vishal Mehta vice president, head of clinical operations.
Biomarin Pharmaceutical Inc., of San Rafael, Calif., appointed Lon Cardon chief scientific strategy officer.
Bolt Biotherapeutics Inc., of Redwood City, Calif., appointed Lawrence Fong, Roy S. Herbst and Bruce D. Roth to its scientific advisory board.
Calidi Biotherapeutics Inc., of San Diego, appointed George Ng to its board.
Cue Biopharma, of Cambridge, Mass., appointed Anish Suri president and chief scientific officer.
Grail Inc., of Menlo Park., Calif., appointed Matthew P. Young chief operating officer and chief financial officer, effective Oct. 28.
Immunoprecise Antibodies Ltd., of Victoria, British Columbia, appointed Brian Lundstrom to its board.
Iomx Therapeutics AG, of Martinsried, Germany, appointed Apollon Papadimitriou CEO and Marcus Irsfeld chief financial officer. It also elected Steven St. Peter chair, Henrijette Richter vice chair and Patrick A. Baeuerle a new member of its supervisory board.
NBE Therapeutics AG, of Basel, Switzerland, appointed Steffen Heeger chief medical officer.
Oncology Pharma Inc., of San Francisco, elected Stefan Gruenwald to its board.
Optinose Inc., of Yardley, Pa., appointed Michael Richardson vice president, business development.
TCR2 Therapeutics Inc., of Cambridge, Mass., appointed Angela Justice chief people officer.
Verrica Pharmaceuticals Inc., of West Chester, Pa., appointed Eugene Scavola executive vice president, technical operations.
Zosano Pharma Corp., of Fremont, Calif., appointed Steven Lo president and CEO and to its board, effective Oct. 21.